Last reviewed · How we verify
Amekrin (AMSACRINE)
Amekrin (AMSACRINE) is a small molecule drug that targets DNA topoisomerase 1, a critical enzyme involved in DNA replication and repair. It is classified as an amsacrine drug and works by intercalating into DNA, thereby inhibiting the enzyme's activity and inducing DNA damage. Amekrin is used to treat certain types of cancer, although its commercial status and approved indications are unclear. The drug has a half-life of approximately 4.7 hours, but its bioavailability and generic manufacturing status are unknown. Further research is needed to determine its safety and efficacy profile.
At a glance
| Generic name | AMSACRINE |
|---|---|
| Drug class | amsacrine |
| Target | DNA topoisomerase 2-beta, Solute carrier family 22 member 1, DNA topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1987 |
Approved indications
Common side effects
Key clinical trials
- IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. (PHASE3)
- Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia (PHASE3)
- Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL (PHASE2,PHASE3)
- Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML (PHASE1,PHASE2)
- DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML (PHASE1,PHASE2)
- Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia (PHASE3)
- Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia (PHASE3)
- A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amekrin CI brief — competitive landscape report
- Amekrin updates RSS · CI watch RSS